CTN 293: REPRIEVE trial
Randomized Trial to Prevent Vascular Events in HIV
About the Study
REPRIEVE is the first large-scale randomized clinical research trial to test a strategy for heart disease prevention among people living with HIV. Specifically, REPRIEVE will test whether a daily dose of a statin (pitavastatin) reduces the risk of heart disease among people living with HIV.
The Randomized Trial to Prevent Vascular Events (REPRIEVE) enrolled 7,769 people living with HIV at approximately 100 clinical research sites, in the United States and abroad over a span of six years, to test whether pitavastatin, a medication
that lowers cholesterol, (vs. placebo) can prevent cardiovascular disease in this population.
Background
AIDS-related complications and deaths are declining, while heart disease among people living with HIV is emerging as a major public health concern. This is happening despite effective treatment for HIV. People living with HIV are 50 to 100% more likely to develop cardiovascular disease ” this includes heart attack and stroke ” compared with people who do not have HIV. Increased chronic inflammation related to HIV may be contributing to the increased risk of heart disease.
Study Approach
In people without HIV, statin medications reduce cholesterol and prevent heart disease. In smaller studies among people with HIV, statins have also been shown to decrease inflammation; we need to confirm these findings among people living with HIV.
Participants in REPRIEVE were randomized to receive pitavastatin or a placebo pill. Pitavastatin is a statin that is approved by the US based Federal Drug Authority (FDA) and approved for use as an investigational drug in Canada. Pitavastatin is considered safe for use with all prescribed antiretroviral therapy regimens.
More information: www.reprievetrial.org
Results
Pitavastatin reduced the incidence of the primary endpoint, major adverse cardiovascular events (MACE) like heart attacks
or strokes, by 36% compared to placebo over an average of approximately 5 years of follow up. No unexpected safety concerns were seen. The results of the REPRIEVE Trial have helped shape clinical guidelines for cardiovascular risk
management in people living with HIV.
Conclusion
In people living with HIV at low-to-moderate traditional risk for cardiovascular disease, pitavastatin prevents major adverse
cardiovascular disease events (including heart attacks and strokes) and is well-tolerated by most.
Investigators
Here’s who is leading this study.
Can’t find what you’re looking for?
Email info@ctnplus.ca.
